(co-advised: Irvine Lab)
Ushered in by a wave of checkpoint inhibitors and combination strategies, cancer immunotherapies have quickly become one of the main treatment approaches in the clinic. Recently, localized delivery of therapeutic agents has shown potential in providing strong efficacy with limited systemic toxicity. Moreover, some of these treatments elicited abscopal effects, suggesting that intratumoral approaches could be used to mediate immunity at secondary sites. To this end, my project aims to engineer an intratumoral immunotherapy strategy that leverages immune cell trafficking to enhance efficacy at metastatic sites.